Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

Non-invasive prenatal testing (NIPT), also known as non-invasive prenatal testing (NIPS), is a method of determining the risk of a fetus being born with certain genetic abnormalities. This test analyzes small pieces of DNA circulating in a pregnant woman's blood.

Download PDF Brochure @  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=145607690

Market Segmentation

On the basis of product and service, the NIPT market is segmented into products and services. The services segment is expected to grow at the highest CAGR during the forecast period. Factors such as the rising incidence of genetic disorders, increasing focus on prenatal screening, and government initiatives to provide prenatal testing services are contributing to the growth of this market.

On the basis of application, the NIPT market is segmented into trisomy, microdeletion syndrome, and other applications. The trisomy segment accounted for the largest share of the non-invasive prenatal testing market in 2018. This segment is also expected to register the highest CAGR during the forecast period. The large share and high growth of this segment can primarily be attributed to the increasing maternal age and the rising incidence of chromosomal abnormalities.

Regional Analysis

North America dominated the market, followed by Europe. The large share of this market can primarily be attributed to the strong economies in the US and Canada, which have allowed for significant investments in technology in this region. Growth in the North American market is supported by the presence of a better reimbursement structure and a favorable funding scenario for research activities, rising awareness about NIPT, and the increasing demand for the early detection of birth defects in this region.

Key Market Players

The prominent players in the market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), GE Healthcare (US), BGI (China), Agilent Technologies, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), PerkinElmer Inc. (US), Laboratory Corporation of America Holdings (US), Natera, Inc. (US), and Yourgene Health (UK)

Get Data as per your Format and Definition | REQUEST FOR CUSTOMIZATION @ https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=145607690

Expected Revenue Growth:

The global non-invasive prenatal testing market is estimated to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period.

Illumina, Inc. (US)

Illumina is one of the major players in the non-invasive prenatal testing market. The company offers a range of highly interconnected products related to sequencing, genotyping, gene expression, and molecular diagnostics. It also offers whole-genome sequencing, genotyping, NIPT, and support services which further strengthen its market position.